Business Context and Reporting Period
Company: Minerva Neurosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 16, 2015
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement).
Key Financial Metrics and Transaction Details
- Total Facility Size: Up to $15 million in term loans.
- Initial Drawdown (Term A Loans): $10 million drawn on January 16, 2015.
- Interest Rate (Term A): Fixed at 7.05% per annum.
- Facility Fee: $75,000 paid upfront.
- Final Payment Fee: 4.45% of total amount borrowed (increases to 5.10% if interest-only period is extended).
- Equity Issuance: Warrants issued for 40,790 shares of Common Stock with an exercise price of $5.516 per share.
- Collateral: First priority security interest in substantially all assets (excluding intellectual property) and equity interests in subsidiaries.
Material Changes and Loan Structure
The Company has entered a new debt facility with Oxford Finance LLC and Silicon Valley Bank. Key structural terms include:
- Tranche B Availability: Up to $5 million available on or prior to March 31, 2016, contingent on achieving primary endpoints for Phase IIa trials of MIN-117 and MIN-202.
- Repayment Schedule: Interest-only payments through February 1, 2016, followed by 30 months of equal principal and interest payments. Maturity date is August 1, 2018.
- Extension Conditions: If the Company raises at least $30 million in capital (including $20 million in equity) and completes first dosing of the MIN-117 Phase I/II trial by December 31, 2015, the interest-only period extends by six months and the repayment period shortens by six months.
- Prepayment Penalties: 3% fee if prepaid within 24 months; 2% between 24-36 months; 1% thereafter.
Guidance, Risks, and Covenants
Covenants and Restrictions: The agreement includes affirmative and restrictive covenants regarding financial reporting, inventory, taxes, insurance, and acquisitions. The Company is restricted from paying dividends or making distributions on capital stock, subject to limited exceptions.
Risks and Contingencies:
- Default Triggers: Failure to meet payment obligations, covenant breaches, or material adverse changes allow lenders to declare all principal and interest immediately due.
- Intellectual Property: While IP is not pledged as collateral, the Company cannot pledge or encumber IP assets, though it may grant certain licenses.
- Unregistered Securities: Warrants were sold to accredited investors under Section 4(2) of the Securities Act of 1933 and are not registered.
Investor Verification Checklist
- Verify the Company's ability to meet the Phase IIa trial endpoints required to access the remaining $5 million tranche.
- Confirm progress toward the $30 million capital raise and MIN-117 first dosing milestones required to extend the interest-only period.
- Review the impact of the 7.05% interest rate and 4.45% final payment fee on future cash flow projections.
- Assess the dilution impact of the 40,790 warrants issued at $5.516 per share.
- Monitor compliance with restrictive covenants, specifically the prohibition on dividends and restrictions on additional indebtedness.